Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

Humira is a versatile drug used to treat multiple autoimmune diseases, such as rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.

Humira (adalimumab) has dominated in the inflammatory diseases including psoriasis and rheumatoid arthritis markets for a decade, and AbbVie needs newer drugs that outperform it and rivals in each ...

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

However, more research is needed to define the cause-and-effect relationship between psoriasis and other diseases. Tumor necrosis factor-a (TNF-a) inhibitors used to treat autoimmune ...

Psoriasis is usually treated with a combination of self-care interventions, medications, and ultraviolet (UV) light therapy. While there is no cure for psoriasis, it can be treated effectively ...

In contrast, Skyrizi saw a 50.8% global increase to $3.205 billion, and Rinvoq rose 45.3% to $1.614 billion. Products like Humira, Skyrizi, and Rinvoq are used to treat plaque psoriasis, ankylosing ...

Tumor necrosis factor-a (TNF-a) inhibitors used to treat autoimmune disorders—including Remicade (infliximab), Humira (adalimumab), and Enbrel (etanercept)—can also trigger psoriasis symptoms ...

In contrast, Skyrizi saw a 50.8% global increase to $3.205 billion, and Rinvoq rose 45.3% to $1.614 billion. Products such as Humira, Skyrizi, and Rinvoq are used to treat plaque psoriasis, ankylosing ...